EMA Recommends Dozens Of Suspensions Over Flawed Synchron Studies
Generic Marketing Authorizations To Be Suspended Following Similar Criticism From US FDA
Executive Summary
The EMA’s CHMP has recommended the suspension of marketing authorizations for around 100 generics after identifying “irregularities” in how bioequivalence studies were conducted by Synchron Research Services.
You may also be interested in...
Another Indian CRO Under EMA Lens Over Dirty Data Concerns
Micro Therapeutic Research Labs is now under the scanner over alleged data integrity concerns. European Medicines Agency (EMA) is evaluating medicines based on studies done by the Indian firm.
Semler Dirty Data: EMA Suspends Over 200 Products; Stings Indian CROs
Dirty data issues continue to plague Indian contract research organizations, denting the reputation of the beleaguered local industry and piling up challenges for marketing authorization holders. The European Medicines Agency (EMA) has now suspended close to 300 products that relied on flawed bioequivalence studies done by the Bengaluru-based Semler Research.
EU confirms suspension of 700 products hit by Indian CRO issues
Around 700 generic drugs will no longer be available in Europe from 21 August after the European Commission issued a decision confirming the products' suspension in light of concerns over data manipulation by the Indian CRO GVK Biosciences.